{"id":872433,"date":"2025-08-07T07:18:25","date_gmt":"2025-08-07T11:18:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/"},"modified":"2025-08-07T07:18:25","modified_gmt":"2025-08-07T11:18:25","slug":"biolinerx-to-report-second-quarter-2025-results-on-august-14-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/","title":{"rendered":"BioLineRx to Report Second Quarter 2025 Results on August 14, 2025"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p class=\"prntac\">\n        <i>Management to Hold Conference Call at <span class=\"xn-chron\">8:30 a.m. EDT<\/span><\/i>\n      <\/p>\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">TEL AVIV, Israel<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Aug. 7, 2025<\/span><\/span> \/PRNewswire\/ &#8212; BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended <span class=\"xn-chron\">June 30, 2025<\/span> on <span class=\"xn-chron\">Thursday, August 14, 2025<\/span>, before the U.S. markets open.<\/p>\n<div id=\"prni_dvprnejpgdcbdleft\" dir=\"ltr\" style=\"width: 100%;text-align: left\">\n        <img decoding=\"async\" id=\"prnejpgdcbdleft\" style=\"width: 400px;height: 107px\" title=\"BioLineRx Ltd Logo\" src=\"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg\" alt=\"BioLineRx Ltd Logo\" align=\"middle\" \/>\n      <\/div>\n<p>The Company will host a conference call at <span class=\"xn-chron\">8:30 a.m. EDT<\/span> featuring remarks by <span class=\"xn-person\">Philip Serlin<\/span>, Chief Executive Officer.<\/p>\n<p>To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the <a href=\"https:\/\/url.avanan.click\/v2\/r01\/___https:\/ir.biolinerx.com\/events\/event-details\/biolinerx-report-second-quarter-2025-results-august-14-2025___.YXAzOmJpb2xpbmVyeDphOm86MGNhNmFhMzJiOGQ2NzcyZjZmZWZjZDU3NjIyNWU5OGM6NzpiOTNlOmFiYWJiY2Y3NTY4YWM2MTBjZmM1MjU0MzNmNGZmOWZjYTZiNmE2M2JmMGM4ZGU3NDhjYzRiMDI0NGE4OTUzMTg6dDpUOk4\" target=\"_blank\" rel=\"nofollow\">event page<\/a> on the Company&#8217;s website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until <span class=\"xn-chron\">August 16, 2025<\/span>; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.<\/p>\n<p>\n        <b>About BioLineRx<\/b>\n      <\/p>\n<p>BioLineRx Ltd. (NASDAQ\/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company&#8217;s first approved product is APHEXDA<sup>\u00ae<\/sup> (motixafortide), with an indication in the U.S. for stem cell mobilization for\u00a0autologous transplantation in multiple myeloma, which is being developed and commercialized by Ayrmid Ltd. (globally, excluding <span class=\"xn-location\">Asia<\/span>) and Gloria Biosciences (in <span class=\"xn-location\">Asia<\/span>). BioLineRx is utilizing its end-to-end expertise in development, regulatory affairs, manufacturing and commercialization to advance its innovative pipeline and ensure life-changing discoveries move beyond the bench to the bedside.<\/p>\n<p>Learn more about who we are, what we do, and how we do it at\u202f<a href=\"http:\/\/www.biolinerx.com\/\" target=\"_blank\" rel=\"nofollow\">www.biolinerx.com<\/a> or on\u202f<a href=\"https:\/\/www.linkedin.com\/company\/112275\/admin\/\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>.<\/p>\n<p>\n        <b>CONTACTS:<br \/><\/b><br \/>\n        <u><br \/>\n          <span class=\"xn-location\">United States<\/span><br \/>\n          <br \/>\n        <\/u><br \/>\n        <span class=\"xn-person\">Irina Koffler<\/span><br \/>\n        <br \/>LifeSci Advisors, LLC<br \/><a href=\"mailto:IR@biolinerx.com\" target=\"_blank\" rel=\"nofollow\">IR@biolinerx.com<\/a><\/p>\n<p><u><span class=\"xn-location\">Israel<\/span><br \/><\/u><span class=\"xn-person\">Moran Meir<\/span><br \/>LifeSci Advisors, LLC<br \/><a href=\"mailto:moran@lifesciadvisors.com\" target=\"_blank\" rel=\"nofollow\">moran@lifesciadvisors.com<\/a><\/p>\n<p>Logo: <a href=\"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg\" target=\"_blank\" rel=\"nofollow\">https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg<\/a><\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO46393&amp;sd=2025-08-07\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025-302524198.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025-302524198.html<\/a><\/p>\n<p>SOURCE  BioLineRx Ltd.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO46393&amp;Transmission_Id=202508070700PR_NEWS_USPR_____IO46393&amp;DateId=20250807\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 7, 2025 \/PRNewswire\/ &#8212; BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company&#8217;s website. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioLineRx to Report Second Quarter 2025 Results on August 14, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-872433","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioLineRx to Report Second Quarter 2025 Results on August 14, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioLineRx to Report Second Quarter 2025 Results on August 14, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 7, 2025 \/PRNewswire\/ &#8212; BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company&#8217;s website. &hellip; Continue reading &quot;BioLineRx to Report Second Quarter 2025 Results on August 14, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-07T11:18:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioLineRx to Report Second Quarter 2025 Results on August 14, 2025\",\"datePublished\":\"2025-08-07T11:18:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\\\/\"},\"wordCount\":347,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2154863\\\/BioLineRx_Ltd_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\\\/\",\"name\":\"BioLineRx to Report Second Quarter 2025 Results on August 14, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2154863\\\/BioLineRx_Ltd_Logo.jpg\",\"datePublished\":\"2025-08-07T11:18:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2154863\\\/BioLineRx_Ltd_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2154863\\\/BioLineRx_Ltd_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioLineRx to Report Second Quarter 2025 Results on August 14, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioLineRx to Report Second Quarter 2025 Results on August 14, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/","og_locale":"en_US","og_type":"article","og_title":"BioLineRx to Report Second Quarter 2025 Results on August 14, 2025 - Market Newsdesk","og_description":"PR Newswire Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 7, 2025 \/PRNewswire\/ &#8212; BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company&#8217;s website. &hellip; Continue reading \"BioLineRx to Report Second Quarter 2025 Results on August 14, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-07T11:18:25+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioLineRx to Report Second Quarter 2025 Results on August 14, 2025","datePublished":"2025-08-07T11:18:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/"},"wordCount":347,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/","name":"BioLineRx to Report Second Quarter 2025 Results on August 14, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg","datePublished":"2025-08-07T11:18:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2154863\/BioLineRx_Ltd_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-to-report-second-quarter-2025-results-on-august-14-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioLineRx to Report Second Quarter 2025 Results on August 14, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/872433","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=872433"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/872433\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=872433"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=872433"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=872433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}